Gilead Sciences (NASDAQ:GILD) Updates FY 2025 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 7.700-8.100 for the period, compared to the consensus earnings per share estimate of 7.600. The company issued revenue guidance of $28.2 billion-$28.6 billion, compared to the consensus revenue estimate of $28.4 billion.

Analysts Set New Price Targets

Several research analysts have weighed in on GILD shares. BMO Capital Markets increased their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $84.00 price objective on shares of Gilead Sciences in a research note on Monday, February 3rd. Truist Financial increased their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Wolfe Research began coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. Finally, Wells Fargo & Company boosted their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Trading Up 0.7 %

Shares of NASDAQ:GILD traded up $0.66 during mid-day trading on Tuesday, reaching $96.14. 6,050,620 shares of the company’s stock were exchanged, compared to its average volume of 6,925,933. The firm has a market capitalization of $119.82 billion, a price-to-earnings ratio of 1,068.22, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $100.51. The business’s fifty day moving average price is $93.07 and its 200-day moving average price is $86.99. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. On average, research analysts predict that Gilead Sciences will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 572,824 shares of company stock valued at $53,611,715 over the last quarter. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.